HK1052314A1 - 改變t細胞介導的病理的方法和組合物 - Google Patents

改變t細胞介導的病理的方法和組合物

Info

Publication number
HK1052314A1
HK1052314A1 HK03104475.3A HK03104475A HK1052314A1 HK 1052314 A1 HK1052314 A1 HK 1052314A1 HK 03104475 A HK03104475 A HK 03104475A HK 1052314 A1 HK1052314 A1 HK 1052314A1
Authority
HK
Hong Kong
Prior art keywords
altering
composition
cell mediated
mediated pathology
pathology
Prior art date
Application number
HK03104475.3A
Other languages
English (en)
Inventor
P Gold Daniel
J Shopes Robert
Original Assignee
Favrille Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Favrille Inc filed Critical Favrille Inc
Publication of HK1052314A1 publication Critical patent/HK1052314A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK03104475.3A 2000-08-11 2003-06-21 改變t細胞介導的病理的方法和組合物 HK1052314A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22472300P 2000-08-11 2000-08-11
US22472200P 2000-08-11 2000-08-11
US26613301P 2001-02-01 2001-02-01
PCT/US2001/025203 WO2002013861A2 (en) 2000-08-11 2001-08-10 Method and composition for altering a t cell mediated pathology

Publications (1)

Publication Number Publication Date
HK1052314A1 true HK1052314A1 (zh) 2003-09-11

Family

ID=27397392

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104475.3A HK1052314A1 (zh) 2000-08-11 2003-06-21 改變t細胞介導的病理的方法和組合物

Country Status (10)

Country Link
US (1) US20030012782A1 (zh)
EP (1) EP1309373A2 (zh)
JP (1) JP2004506021A (zh)
KR (1) KR20030064377A (zh)
AU (2) AU8330401A (zh)
CA (1) CA2416794A1 (zh)
HK (1) HK1052314A1 (zh)
MX (1) MXPA03001142A (zh)
SG (1) SG143058A1 (zh)
WO (1) WO2002013861A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
GB0721686D0 (en) * 2007-11-05 2007-12-12 Medinnova As Polypeptides
WO2015058780A1 (en) * 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
WO2018026018A1 (ja) * 2016-08-05 2018-02-08 国立大学法人東北大学 Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
JPWO2019151392A1 (ja) * 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的ｍｈｃ発現調節法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631690A (en) * 1898-11-14 1899-08-22 Joseph Franklin Polishing or abrading device.
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IT1136411B (it) * 1980-06-17 1986-08-27 Oddo Borghetto Complesso di elementi distanziatori e allineatori per blocchetti particolarmente adatti per pareti o pannelli in vetro cemento
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4816249A (en) * 1981-11-17 1989-03-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5908763A (en) * 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
UA29377C2 (uk) * 1984-09-19 2000-11-15 Новартіс Аг Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
JPH01193227A (ja) * 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5861164A (en) * 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
EP0482068A1 (en) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5281699A (en) * 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
EP0651656A1 (en) * 1992-07-08 1995-05-10 Schering Corporation Use of gm-csf as a vaccine adjuvant
US6099846A (en) * 1992-10-14 2000-08-08 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
US5728377A (en) * 1993-07-20 1998-03-17 Board Of Regents, The University Of Texas System Methods and compositions incorporating IP-10
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
DE4406172C2 (de) * 1994-02-25 2003-10-02 Sanol Arznei Schwarz Gmbh Polyester
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
US5789206A (en) * 1995-07-07 1998-08-04 Myriad Genetics, Inc. Method for ligating adaptors to nucleic acids which methods are useful for obtaining the ends of genes
US5900238A (en) * 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6083703A (en) * 1996-02-09 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
JP3948751B2 (ja) * 1996-02-16 2007-07-25 バイオミラ・ユーエスエイ・インコーポレイテッド Ｂ細胞悪性疾患用ワクチン
US5776746A (en) * 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
AU4266597A (en) * 1996-09-11 1998-04-14 General Hospital Corporation, The Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
EP0931159A2 (en) * 1996-09-11 1999-07-28 The General Hospital Corporation Non-mammalian dna virus having an altered coat protein
US6063905A (en) * 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6361948B1 (en) * 1997-08-13 2002-03-26 James V. Tricoli Prognostic compositions for prostate cancer and methods of use thereof
KR100712256B1 (ko) * 1997-10-02 2007-04-27 알토 바이오사이언스 코포레이션 가용성 단일쇄 ｔ-세포 수용체 단백질
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
IL127142A0 (en) * 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
US6342216B1 (en) * 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
WO2001093913A2 (en) * 2000-06-05 2001-12-13 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof

Also Published As

Publication number Publication date
MXPA03001142A (es) 2004-08-02
SG143058A1 (en) 2008-06-27
WO2002013861A2 (en) 2002-02-21
CA2416794A1 (en) 2002-02-21
EP1309373A2 (en) 2003-05-14
KR20030064377A (ko) 2003-07-31
AU8330401A (en) 2002-02-25
JP2004506021A (ja) 2004-02-26
WO2002013861A3 (en) 2002-12-05
AU2001283304B2 (en) 2005-05-05
US20030012782A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
IL154336A0 (en) Progenitor cells and method and uses related thereto
AU5752601A (en) Splice-region antisense composition and method
PH12001000366B1 (en) Composition and method for bleaching a substrate
AU6832101A (en) Composition and method
IL150430A0 (en) Cell division inhibitors and process for producing the same
AU4163402A (en) Composition and method
GB2362124B (en) Hand tool and method for making same
AU2002229483A1 (en) Fuel cell arrangement and method for operation thereof
AU4215901A (en) Methods and compositions for immunoregulation
AU2001279850A1 (en) Method and arrangement for studsystem
SG96218A1 (en) Sic-formed materials and method for manufacturing same
SG2010046837A (en) Method and composition for altering a b cell mediated pathology
EP1267305A4 (en) CELL LINE EXTRACTION METHOD
AU4247001A (en) Glucocorticoids in a modified release-formulation
AU2001233932A1 (en) Method and composition
AU2001231803A1 (en) Method in trade
AU8330401A (en) Method and composition for altering a t cell mediated pathology
GB0004988D0 (en) Composition and method for bleaching a substrate
GB0004990D0 (en) Composition and method for bleaching a substrate
AU2002239775A1 (en) Chemical-library composition and method
GB2372810B (en) Support and method for cell based assays
AU2001283030A1 (en) Process for making 3-hydroxyalkanenitriles and hydroxyaminoalkanes
EP1272512A4 (en) IMMUNOKIN COMPOSITION AND METHOD
AU2001263232A1 (en) A plastisol composition and method for using same
TW445934U (en) Improved structure for fast pincer